BD Diagnostics, a part of global medical technology company BD (Becton, Dickinson and Company), and Biodiversity SpA, a biotechnology company for molecular diagnostics, announced a regional collaboration to develop and commercialize a comprehensive molecular diagnostic plan for immunocompromised patients on the BD MAX System.
This portfolio is aimed to improve monitoring of infections in transplant patients and will increase BD's time to market with the BD MAX platform's open-capability architecture.
"This collaboration combines the BD MAX System's advanced automation and open system capabilities with Biodiversity's broad portfolio and track record at bringing to market molecular assays for the management of transplant patients," states Tom Polen, President, BD Diagnostics -- Diagnostic Sybstems.
"This will empower laboratories with a new choice to improve the efficiency, accuracy and speed to diagnose these types of infections. Our collaboration with Biodiversity also represents another milestone in developing the BD MAX System as the platform of choice to meet our customers' current and future molecular needs," Polen added.
The mode of treatment for patients having undergone transplant, is treating with drugs designed to suppress their immune system to prevent rejection. In this immunocompromised state, patients can be at high risk for infection. To prevent this condition, Assays developed under the collaboration for the BD MAX System expanding testing capabilities for molecular laboratories with the ability to run many different assays and sample simultaneously. This results in faster testing results and earlier diagnosis for patients.
"With molecular testing established as the standard of care for managing transplant patients, the BD MAX System will allow testing to be conducted with a standardized and fully automated workflow. At Biodiversity, our extensive assay experience in molecular transplant diagnostics is ideally positioned to capitalize on the technological advantages of the BD MAX System, making it possible to deliver a major advance in terms of efficiency, accuracy and ease-of-use for laboratories," said Giovanni Mantero, Chief Executive Officer, Biodiversity SpA.
According to the agreement, Biodiversity will develop a portfolio of molecular assays for the detection of infections in immunocompromised patients using the BD MAX System's open architecture.
“BD plans to bring new assays to the BD MAX System in a broad range of disease categories. With this announcement, there are now more than 15 assays in the BD MAX System's content-rich menu pipeline. Combined with open capability, full automation and standardized workflow, the BD MAX System will enable laboratories to consolidate and standardize their molecular tests to build programs that meet both their current and future clinical needs,” Polen continues.
Want to learn more about the latest in communications and technology? Then be sure to attend ITEXPO West 2011, taking place Sept. 13-15, 2011, in Austin, Texas. ITEXPO offers an educational program to help corporate decision makers select the right IP-based voice, video, fax and unified communications solutions to improve their operations. It's also where service providers learn how to profitably roll out the services their subscribers are clamoring for – and where resellers can learn about new growth opportunities. To register, click here.
Anamika Singh is a contributing editor for HealthTechZone. To read more of Anamika's articles, please visit her columnist page.Edited by
Rich Steeves
